Neramexane fails phase III Alzheimer's trial

Forest Labs Off on Alzheimer's Bust: "Forest said the drug, neramexane, failed to produce statistically significant results during a six-month test covering 415 patients. "

The phase III trial tested neramexane in combination with acetylcholinesterase inhibitors. Neramexane targets the NMDA receptor, as does Forest's launched Alzheimer's drug Namenda. The company says it will continue trials on the drug and is currently enrolling a phase II/III trial that will test neramexane as a single agent.